Background. Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) account for the majority of pancreatic cystic neoplasms and are mostly incidentally detected on imaging performed for other indications. Current guidelines recommend lifelong surveillance, but recent evidence suggests that the malignancy risk in BD-IPMN stable for ≥5 years may be comparable to that of the general population. Surveillance nonetheless imposes a considerable economic, organizational, and psychological burden on both healthcare systems and patients. Aims of the study. This study aims to explore the attitudes of experts and patients towards discontinuing surveillance in BD-IPMN. Specifically, it assesses expert opinions and management approaches in this context, alongside patients' perceptions, willingness, and psychological burden. The goal is to identify the barriers to implementing this strategy in clinical practice and to inform the development of future, internationally shared guidelines. Materials and Methods. This is an international, cross-sectional survey study among experts and patients, conducted by the University of Padova. Experts were clinicians involved in the management of pancreatic cystic neoplasms; patients were individuals with a diagnosis of BD-IPMN currently undergoing active surveillance. The expert survey assessed guideline adherence, attitudes toward surveillance discontinuation, and management approaches in hypothetical clinical scenarios; the patient survey assessed perceived follow-up burden, comfort with hypothetical discontinuation if recommended by the treating physician, and reasons for discomfort. Results. The expert survey was completed by 201 specialists from 25 countries; the patient survey included 181 patients under surveillance in Italy (n = 110) and Japan (n = 71). Among experts, 84.6% (n = 170) had considered discontinuing surveillance, yet only 30.3% (n = 61) and 30.8% (n = 62) applied it to 1–5% and 6–10% of their patients, respectively; 63.7% (n = 128) required 5 years of dimensional stability beforehand, and hypothetical clinical scenarios revealed substantial management heterogeneity. Among patients, 54.2% (n = 98) reported discomfort with discontinuation, and 47.5% (n = 86) would refuse it even if recommended by their physician, mainly due to loss of reassurance (50.8%, n = 92) and fear of undiagnosed malignancy (42.5%, n = 77). Japanese patients reported greater reassurance from surveillance (69.0%, n = 49 “very reassured” vs 51.8%, n = 57) and lower trust in physicians than Italian patients (12.7%, n = 9 "completely trust" vs 51.8%, n = 57). Conclusions. Widespread reluctance and substantial heterogeneity in decision-making regarding surveillance discontinuation were observed among both experts and patients. A single, internationally shared guideline is needed, one that explicitly accounts for the cultural differences identified as a key outcome of this study, since these may represent a barrier to adherence and to motivation to follow evidence-based recommendations.
Background. Le neoplasie mucinose papillari intraduttali di tipo Branch-duct (BD-IPMNs) rappresentano la maggior parte delle neoplasie cistiche pancreatiche e sono per la maggior parte riscontrate incidentalmente durante esami di imaging eseguiti per altre indicazioni. Le linee guida attuali raccomandano una sorveglianza a vita, ma evidenze recenti suggeriscono che il rischio di malignità nelle BD-IPMN stabili da ≥5 anni possa essere sovrapponibile a quello della popolazione generale. La sorveglianza comporta comunque un notevole carico economico, organizzativo e psicologico, sia per i sistemi sanitari sia per i pazienti. Obiettivi dello studio. Questo studio si propone di esplorare l'atteggiamento di esperti e pazienti riguardo l'interruzione della sorveglianza nelle BD-IPMN. Nello specifico, vengono valutate le opinioni e le condotte gestionali degli esperti in questo contesto, insieme alle percezioni, alla volontà e al burden psicologico riportati dai pazienti. L'obiettivo finale è identificare le barriere all'implementazione di questa strategia nella pratica clinica e fornire indicazioni utili allo sviluppo di future linee guida internazionali condivise. Materiali e Metodi. Si tratta di uno studio survey internazionale, trasversale, condotto dall'Università di Padova su esperti e pazienti. Gli esperti erano clinici coinvolti nella gestione delle neoplasie cistiche pancreatiche; i pazienti erano individui con diagnosi di BD-IPMN attualmente in sorveglianza attiva. Il questionario rivolto agli esperti ha valutato l'aderenza alle linee guida, l'atteggiamento verso l'interruzione della sorveglianza e le condotte gestionali in scenari clinici ipotetici; il questionario rivolto ai pazienti ha valutato il burden percepito del follow-up, il livello di comfort verso un'ipotetica interruzione se raccomandata dal medico curante, e i motivi di disagio. Risultati. Il questionario per esperti è stato completato da 201 specialisti provenienti da 25 paesi; il questionario per pazienti ha incluso 181 pazienti sotto sorveglianza in Italia (n = 110) e Giappone (n = 71). Tra gli esperti, l'84,6% (n = 170) aveva considerato l'interruzione della sorveglianza, ma solo il 30,3% (n = 61) e il 30,8% (n = 62) la applicava rispettivamente all'1-5% e al 6-10% dei propri pazienti; il 63,7% (n = 128) richiedeva 5 anni di stabilità dimensionale prima dell'interruzione, e gli scenari clinici ipotetici hanno rivelato una sostanziale eterogeneità gestionale. Tra i pazienti, il 54,2% (n = 98) ha riportato disagio verso l'interruzione, e il 47,5% (n = 86) la rifiuterebbe anche se raccomandata dal proprio medico, principalmente per la perdita della rassicurazione del monitoraggio (50,8%, n = 92) e il timore di una malignità non diagnosticata (42,5%, n = 77). I pazienti giapponesi hanno riportato una maggiore rassicurazione dalla sorveglianza (69,0%, n = 49 “molto rassicurato” vs 51,8%, n = 57) e una minore fiducia nei medici rispetto ai pazienti italiani (12,7%, n = 9 "completamente" vs 51,8%, n = 57). Conclusioni. Sono state osservate una diffusa riluttanza e una sostanziale eterogeneità decisionale riguardo all'interruzione della sorveglianza, sia tra gli esperti sia tra i pazienti. È necessaria un'unica linea guida internazionale condivisa, che tenga esplicitamente conto delle differenze culturali identificate come risultato chiave di questo studio, poiché queste potrebbero rappresentare una barriera all'aderenza e alla motivazione nel seguire raccomandazioni evidence-based.
Global Perspectives on Surveillance Discontinuation in BD-IPMN: Expert and Patient Survey Study
MURARO, NICOLA
2025/2026
Abstract
Background. Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) account for the majority of pancreatic cystic neoplasms and are mostly incidentally detected on imaging performed for other indications. Current guidelines recommend lifelong surveillance, but recent evidence suggests that the malignancy risk in BD-IPMN stable for ≥5 years may be comparable to that of the general population. Surveillance nonetheless imposes a considerable economic, organizational, and psychological burden on both healthcare systems and patients. Aims of the study. This study aims to explore the attitudes of experts and patients towards discontinuing surveillance in BD-IPMN. Specifically, it assesses expert opinions and management approaches in this context, alongside patients' perceptions, willingness, and psychological burden. The goal is to identify the barriers to implementing this strategy in clinical practice and to inform the development of future, internationally shared guidelines. Materials and Methods. This is an international, cross-sectional survey study among experts and patients, conducted by the University of Padova. Experts were clinicians involved in the management of pancreatic cystic neoplasms; patients were individuals with a diagnosis of BD-IPMN currently undergoing active surveillance. The expert survey assessed guideline adherence, attitudes toward surveillance discontinuation, and management approaches in hypothetical clinical scenarios; the patient survey assessed perceived follow-up burden, comfort with hypothetical discontinuation if recommended by the treating physician, and reasons for discomfort. Results. The expert survey was completed by 201 specialists from 25 countries; the patient survey included 181 patients under surveillance in Italy (n = 110) and Japan (n = 71). Among experts, 84.6% (n = 170) had considered discontinuing surveillance, yet only 30.3% (n = 61) and 30.8% (n = 62) applied it to 1–5% and 6–10% of their patients, respectively; 63.7% (n = 128) required 5 years of dimensional stability beforehand, and hypothetical clinical scenarios revealed substantial management heterogeneity. Among patients, 54.2% (n = 98) reported discomfort with discontinuation, and 47.5% (n = 86) would refuse it even if recommended by their physician, mainly due to loss of reassurance (50.8%, n = 92) and fear of undiagnosed malignancy (42.5%, n = 77). Japanese patients reported greater reassurance from surveillance (69.0%, n = 49 “very reassured” vs 51.8%, n = 57) and lower trust in physicians than Italian patients (12.7%, n = 9 "completely trust" vs 51.8%, n = 57). Conclusions. Widespread reluctance and substantial heterogeneity in decision-making regarding surveillance discontinuation were observed among both experts and patients. A single, internationally shared guideline is needed, one that explicitly accounts for the cultural differences identified as a key outcome of this study, since these may represent a barrier to adherence and to motivation to follow evidence-based recommendations.| File | Dimensione | Formato | |
|---|---|---|---|
|
TESI.pdf
accesso aperto
Dimensione
2.04 MB
Formato
Adobe PDF
|
2.04 MB | Adobe PDF | Visualizza/Apri |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/116690